
Dive deeper in this topic
Best practices in cfDNA purification
Discover here tips and tricks for optimizing your cfDNA extraction process, enabling maximum yield and purity while minimizing contamination and degradation. Whether you're new to cfDNA extraction or looking to refine your existing protocols, these strategies will help you overcome common obstacles and achieve more consistent, reliable results.

Tips on establishing a reliable cell free DNA (cfDNA) workflow from plasma samples
Analyzing circulating cell free DNA (ccfDNA) offers a non-invasive, dynamic window into the body’s physiological state and its use as a biomarker is gaining rapidly.
Looking for a manual option?
If you do not have a chemagic instrument but would like to benefit from the advantage of chemagic M-PVA Magnetic Bead technology, the manual chemagic cfDNA 5k kit is now available. Process up to 5 ml of sample and avoid spillages and clogs linked to spin column or vacuum-based systems with an easy magnetic bead-based protocol.

chemagic cfDNA 5k Kit (Manual)
The chemagic cfDNA 5k Kit (Manual) can be performed manually without the need for a chemagic instrument. Process from 1 to 5 ml of sample and avoid spillages and clogs linked to spin column or vacuum-based systems with an easy magnetic bead-based protocol. The kit is sufficient for 40 preparations and all reagents are included, with the exception of water for dissolving Proteinase K, and a required magnetic stand such as the chemagic Stand 2x12 or chemagic Stand Type F.
ctDNA reference standards
Mimix™ reference standards are cell line-derived to closely mimic patient samples. For over a decade, Revvity has been producing reference standards in the format of ctDNA for the surveillance of minimal residual disease (MRD) tracked via liquid biopsy. Our reference standards are available with matched negative controls to suit assay requirements.

Mimix Reference Standards
Revvity Mimix Reference Standards are all cell-line derived to maintain genomic coverage across the molecular diagnostics workflow.
Featured resources
References:
- Kwon, HJ., Shin, S.H., Kim, H.H. et al. Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer. Sci Rep 13, 13502 (2023).
- Frank, M. S., Andersen, C. S. A., Ahlborn, L. B., Pallisgaard, N., Bodtger, U., & Gehl, J. Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer. Cancer Research Communications, 2022; 2(10), 1174–1187.
- Callesen LB, Hansen TF, Andersen RF, Pallisgaard N, Kramer S, Schlander S, Rafaelsen SR, Boysen AK, Jensen LH, Jakobsen A, Spindler KG. OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol. Acta Oncol. 2022 Sep;61(9):1152-1156.
- Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Wundsam H, Biebl M, Petzer A, Rumpold H. Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer. Front Oncol. 2022 Aug 30;12:902177.
- Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Weitzendorfer M, Petzer A, Függer R, Rumpold H, Wundsam H. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. Eur J Surg Oncol. 2022 May;48(5):1046-1053.
- Broholm M, Bojesen R, Gögenur M, Weinberger Rosen A, Watt S, Bulut M, Vogelsang R, Quist Jensen H, Orhan A, Bjerrum E, Søs Auður Andersen C, Pallisgaard N, Litman T, Troelsen JT, Gögenur I. Circulating Cell-Free DNA and Systemic Inflammatory Response after Self-Expandable Metal Stent for Malignant Bowel Obstruction. Archives of Microbiology and Immunology 6 (2022): 247-255.
- Lefèvre AC, Pallisgaard N, Kronborg C, Wind KL, Krag SRP, Spindler KG. The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus. Cancers (Basel). 2021 May 18;13(10):2451.
- Yu J, Cho E, Choi J, Lim JE, Lee J, Kang M, Sung HH, Jeong BC, Seo SI, Jeon SS, Lee HM, Jeon HG. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance. Investig Clin Urol. 2021 Mar;62(2):224-232.
- Moon SM, Kim JH, Kim SK, Kim S, Kwon HJ, Bae JS, Lee S, Lee HS, Choi MY, Jeon BH, Jeong BH, Lee K, Kim HK, Kim J, Um SW. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. Anticancer Res. 2020 Jun;40(6):3435-3444.